Rocket Pharmaceuticals (RCKT) Gains from Investment Securities (2014 - 2024)

Rocket Pharmaceuticals (RCKT) reported Gains from Investment Securities of -$1000.0 for Q4 2024, up 99.04% sequentially from -$104000.0 in Q3 2024.

Rocket Pharmaceuticals (RCKT) Gains from Investment Securities (2014 - 2024) Analysis & Trends

Rocket Pharmaceuticals (RCKT) has 3 years of Gains from Investment Securities data on file, last reported at -$1000.0 in Q4 2024.

For the quarter ending Q4 2024, Gains from Investment Securities changed N/A year-over-year to -$1000.0; the trailing twelve-month figure through Sep 2025 stood at -$1000.0 (up 99.95% YoY), and the FY2024 full-year result was -$1.9 million, down 415.38% from the prior year.
Gains from Investment Securities rose to -$1000.0 in Q4 2024, from -$104000.0 in the prior quarter.
In the past five years, Gains from Investment Securities ranged from a high of $1.1 million in Q1 2024 to a low of -$2.9 million in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn
7	Belite Bio	62.72 Bn	62.72 Bn	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-
10	Rocket Pharmaceuticals	367.24 Mn	367.24 Mn	-

Download Data